A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients

SIMPLE SUMMARY: Improvement in melanoma patients with metastatic disease is needed to better assess immunotherapies. Lactate dehydrogenase (LDH) is currently an accepted biomarker for stage IV, but it has limited utility for stage III melanoma patients. Thus, finding biomarkers for metastatic melano...

Descripción completa

Detalles Bibliográficos
Autores principales: Bustos, Matias A., Gross, Rebecca, Rahimzadeh, Negin, Cole, Hunter, Tran, Linh T., Tran, Kevin D., Takeshima, Ling, Stern, Stacey L., O’Day, Steven, Hoon, Dave S. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696545/
https://www.ncbi.nlm.nih.gov/pubmed/33202891
http://dx.doi.org/10.3390/cancers12113361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696545/
https://www.ncbi.nlm.nih.gov/pubmed/33202891
http://dx.doi.org/10.3390/cancers12113361

Ejemplares similares